Comparative Pharmacology
Head-to-head clinical analysis: MODEYSO versus SOJOURN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MODEYSO versus SOJOURN.
MODEYSO vs SOJOURN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
400 mg orally once daily with food
400 mg orally once daily
None Documented
None Documented
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive